Dimerix Limited ( (AU:DXB) ) has provided an announcement.
Dimerix Limited announced its participation in the ASX CEO Connect event, highlighting its Phase 3 clinical asset in kidney disease. The company is working on DMX-200, which has shown promising results in addressing the unmet medical needs of FSGS, a rare and severe kidney disease. With Orphan Drug Designation in the US and Europe, Dimerix is poised for potential market exclusivity and accelerated regulatory pathways, which could significantly impact its market position and offer new hope for patients with limited treatment options.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, including kidney and respiratory diseases. The company is advancing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for respiratory disease, utilizing its Receptor Heteromer Investigation Technology platform.
YTD Price Performance: 16.18%
Average Trading Volume: 1,842,486
Technical Sentiment Signal: Sell
Current Market Cap: A$220.9M
For detailed information about DXB stock, go to TipRanks’ Stock Analysis page.